Biocristin-AQ Injection Vincrsitine Sulfate Injection USP

About Biocristin-AQ Injection Vincrsitine Sulfate Injection USP

Biocristin-AQ Injection is used to treat various cancers, including leukaemia, lymphoma, and solid tumours. Vincristine, a vinca alkaloid, kills cancer cells by interfering with their ability to form microtubules. The "AQ" indicates an intravenous, ready-to-use, preservative-free formulation, typically administered by medical personnel in controlled medical environments. It is a vital part of many chemotherapy regimens, offering important therapeutic benefits.

Regular monitoring by medical specialists is essential to manage potential side effects and improve treatment outcomes.

Features and Advantages

Features:

• Contains Vincristine, a powerful anticancer vinca alkaloid.
• Intravenous administration allows accurate dosing and rapid drug delivery.
• Ready-to-use formulation eliminates reconstitution, simplifying administration.
• Preservative-free ("AQ"), reducing risk of adverse or allergic reactions.
• Effective against multiple cancer types, including leukaemia, lymphoma, and solid tumours.

Benefits:

• Significant therapeutic advantages as part of chemotherapy regimens.
• Vincristine disrupts microtubule synthesis, causing cancer cell death.
• Often used with other chemotherapy drugs for synergistic effects.
• Prolongs remission and improves survival rates in some cancers.
• Lower risk of bone marrow suppression compared to some chemotherapy drugs.
• Causes fewer gastrointestinal side effects relative to other agents.
• Targets cancer cells specifically, sparing healthy cells.
• Well-established and extensively studied, ensuring reliable efficacy and safety.

Uses

• Acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML).
• Hodgkins and non-Hodgkin lymphoma.
• Certain soft tissue sarcomas.
• Solid tumours including Wilms tumour and neuroblastoma.

Side Effects

• Peripheral neuropathy: tingling, numbness, or pain in hands and feet.
• Bone marrow suppression: increases risk of bleeding, infection, and anaemia.
• Gastrointestinal issues: constipation, nausea, vomiting.
• Alopecia (temporary hair loss).
• Jaw pain or difficulty opening the mouth.
• Neurologic effects: convulsions, paralysis (rare).
• Vision changes: blurred vision or other abnormalities.
• Allergic reactions: rash, itching, breathing difficulties.
• Constipation.
• Rarely, tumour lysis syndrome from rapid cancer cell death.

Important Notes

• Patients should be closely monitored during therapy.
• Report any concerning symptoms or side effects immediately.
• Administration should always be by a qualified oncologist or haematologist.

Product Details